Immunisation schedule of the Pediatric Spanish Association: 2021 recommendations
Vaxcyte's Pneumococcal Vaccine Win Points To Prevnar Battle
Vaxcyte's new pneumococcal vaccine may only have phase 1/2 results behind it, but analysts are already predicting it could be a major competitor to rival shots from Pfizer and MSD.
Just-reported data from that study has shown that Vaxcyte's VAX-31 shot was able to stimulate a strong immune response against all 31 serotypes of Streptococcus pneumoniae included in the formulation, in adults aged 50 and over.
It had a safety profile similar to Pfizer's market-leading Prevnar 20, which targets 20 common serotypes, but at the highest dose tested generated stronger protection on 18 out of 20 of them – and for seven serotypes that improvement was statistically significant.
Shares in Vaxcyte shot up by more than a third after the results were announced as the company said it would move ahead next year with a phase 3 programme for VAX-31 in older adults that will also compare the shot with Prevnar 20. A phase 2 study in children will also start early in 2025.
Buoyed by the new data, Vaxcyte – which had almost $1.9 billion in cash at the end of the second quarter – promptly announced plans for a $1 billion public offering to help fund its phase 3 trials.
Pfizer has been the undisputed leader in the pneumococcal vaccine market for years, gradually adding new versions of Prevnar that expand the number of serotypes covered, but analysts think that position is now under threat.
The franchise brought in $6.4 billion in worldwide sales last year, although MSD (known as Merck & Co in the US and Canada) has started to claim market share with Vaxneuvance, which covers 15 serotypes and made sales of $665 million in 2023. In June, MSD got FDA approval for a 21-valent vaccine, called Capvaxive, which is the first jab approved for the over-50s category.
At the moment, pneumococcal vaccination is recommended for the 65 and over age bracket in the US, although – following the Capvaxive approval – the CDC's Advisory Committee on Immunisation Practices (ACIP) is considering lowering the age threshold to 50.
Analysts at Leerink said the profile exhibited by Vaxcyte's vaccine could – if backed up in phase 3 – allow it to claim a "majority share" in a pneumococcal vaccine market they anticipate will be worth more than $10 billion from 2030 onwards.
The company said VAX-31 has the potential to become the first vaccine in the class to combine protection against both currently circulating and historically prevalent serotypes of S pneumoniae, which causes more than 150,000 cases of pneumonia requiring hospitalisation in the US every year and 300,000 deaths in children worldwide.
The pathogen is listed by the WHO and CDC among the most threatening pathogens due to rising levels of antibiotic resistance.
There are around 100 different pneumococcal serotypes, causing non-invasive disease like pneumonia, confined to the lungs, and invasive disease, where the infection can spread to the bloodstream or tissues in the central nervous system.
Vaxcyte said its vaccine covers serotypes involved in around 95% of invasive pneumonia disease (IPD) cases in the US. It expects the pneumococcal vaccine market to reach a value of around $13 billion by 2027, driven primarily by growth in the adult market.
"The public health community continues to highlight the need for broader-protection vaccines to prevent IPD, which is associated with high case-fatality rates, antibiotic resistance, and meningitis," said Vaxcyte's chief operating officer, Jim Wassil.
VAX-31 has the potential to be "a best-in-class pneumococcal vaccine capable of raising the bar for immunogenicity standards," he added.
The company is also developing a 24-valent pneumococcal vaccine, VAX-24, which is in a phase 2 study in paediatric patients, with results due in the first quarter of 2025.
Why Adult Immunisation Is Important
Every year, the monsoon season brings with it an increased risk of infectious diseases. Recognizing this, public health efforts traditionally focus on protecting children from infection with protective measures including childhood vaccination. While this is vital, another important step towards ensuring layered protection across the population and safeguarding health is often overlooked – adult immunization. Unfortunately, while vaccines during one's early years are well accepted, there remains low awareness about adult vaccination, or attitudes of suspicion and hesitance, often owing to misconceptions. Therefore, there are considerably low adult vaccination adoption rates in India. As a result, many adults, including vulnerable groups such as the elderly and people living with chronic diseases, stay vulnerable to the effects of vaccine-preventable diseases (VPDs). This is vital to address.Immunization is particularly critical for India's elderly population. Adult immunization is available to protect against several conditions – flu & pneumococcal vaccines, DPT vaccine for diphtheria, pertussis, and tetanus, and vaccines for Human papillomavirus (HPV), Hepatitis B, measles, mumps, and rubella (MMR), and Herpes. Given that the nation's immunization programme was only implemented in 1978, most Indians over 50 years of age were not vaccinated as children. Further, ageing makes people's immune systems more susceptible to deterioration and puts them at a greater risk of chronic conditions like diabetes, chronic heart, lung, kidney, and liver diseases. Inflammation with age poses another challenge. Collectively, these factors can contribute to lowered immunity and a decreased response to new or previously encountered infections, which can adversely affect their quality of life and daily functioning. Confronting this is crucial, especially given that infections form the leading cause of death affecting 30% of elderly patients.Vaccines are a proven, safe, and effective tool to protect more people against VPDs, helping your body create antibodies which fight off infections. They offer several key benefits – including safeguarding your health and wellness during travel or in the case of any occupational health risks, and boosting your protection against diseases after these effects have weaned off over your life. Vaccination can also help people curb the spread of the disease across the community, lowering the burden on India's healthcare systems. It also offers you protection not just against the disease, but also other health complications that come with it. To illustrate, in the case of seasonal influenza or the flu – the annual flu vaccine is essential to help people avoid infection and also reduce their risk of being hospitalized, or of catching flu-related pneumonia, heart attacks, or stroke. Pneumococcal infection, which is common among adults, can vary from pneumococcal pneumonia to meningitis – chances of developing pneumonia, for instance, is high in adults who are ageing and have comorbidities. Another infection to protect against is Human Papilloma Virus (HPV), which is a leading cause of cervical and penile cancer and can also result in other types of cancers in women and men. Taking the HPV vaccine shields you from being infected or passing on the virus.Further, adults can even gain the benefits of newer vaccines that had not been introduced during their younger years. Notably, immunization also plays an important role in helping reduce the severity of a disease and reducing the risk of related complications. This is especially important for adults who are at a higher risk of being affected by VPDs, owing to their age, chronic disease, or immunocompromised condition. People with chronic diseases may face exacerbated issues when experiencing infections, which makes it crucial for them to get vaccinated. Take people with diabetes, for example. Hyperglycemia, which is when one's blood sugar level is high, can be associated with severe immune dysfunction – making it important for them to take preventive measures. Taking into consideration that having diabetes (particularly for a longer duration, alongside poor control over one's glucose levels) increases the risk ratio of pneumonia-related hospitalisation by a range of 25% to 75%, this should be a priority.For adults, with the elderly and people with chronic diseases in particular, the benefits of timely adult vaccination are immense. Strengthening awareness and a greater understanding of these protective health measures among both healthcare practitioners and the general public will be a crucial step towards increasing the adoption of adult immunization in India. This can also be supported by the release of guidelines or through educational initiatives geared to equip people with knowledge on these options, such as by opening Centres of Excellence within hospitals where credible information can be shared easily. Spearheading details such as on optimal vaccine dosing schedules, which differ from vaccine to vaccine, and more also mark an important step forward. Adopting adult vaccination can be a key step towards taking care of people's health over the course of their lives.(Dr Ruchita Sharma, Senior Consultant, Department of Internal Medicine, Medanta, Lucknow)
Pneumococcal Vaccine Market Research 2024-2030: Prevnar 13, VAXNEUVANCE, PNEUMOSIL Size, Share & Trends Analysis
Company Logo
Global Pneumococcal Vaccine Market
Global Pneumococcal Vaccine Market
Dublin, Sept. 06, 2024 (GLOBE NEWSWIRE) -- The "Global Pneumococcal Vaccine Market Size, Share & Trends Analysis Report by Vaccine Type, Product (Prevnar 13, VAXNEUVANCE, PNEUMOSIL), End-use (Public Sector, Private Sector), Region, and Segment Forecasts, 2024-2030" report has been added to ResearchAndMarkets.Com's offering.
The global pneumococcal vaccine market size is anticipated to reach USD 12.19 billion by 2030, registering a CAGR of 6.21% from 2024 to 2030
The market is primarily driven by the increasing prevalence of target diseases. Pneumococcus is the main cause of invasive disease, pneumonia, and upper respiratory tract infection and can lead to severe sequelae such as deafness, paralysis, intellectual disability, and other serious complications.
For instance, in September 2023, the World Health Organization (WHO) estimated that Streptococcus pneumoniae is responsible for over 300,000 deaths annually among children under the age of 5 worldwide. The majority of these fatalities occur in developing nations. Globally, S. Pneumoniae is the primary cause of pneumonia-related deaths, surpassing all other causes combined. The highest number of deaths due to this bacterium is observed in countries located in Africa and Asia.
Increasing government awareness programs regarding pneumonia immunization fuels the market growth. For instance, in September 2023, a survey conducted in September and October 2022 found that there's a need to extend the recommendations for the new 20-valent pneumococcal conjugate vaccine (PCV20) to adults who previously received the 13-valent pneumococcal conjugate vaccine (PCV13). The survey showed that healthcare providers need to be more aware of and implement pneumococcal vaccination recommendations better. After considering these findings, the Advisory Committee on Immunization Practices (ACIP) agreed to update the recommendations in late October 2022.
Moreover, product launches by key players is contributing to market growth. For instance, In October 2022, Merck & Co., Inc. Received the European Commission's (EC) approval for its Vaxneuvance, a pneumococcal vaccine. The approval allows product marketing in 27 European Union (EU) member states and Iceland, Norway, & Lichtenstein. Moreover, in September 2021, Minhai Biotechnology Co. Ltd. Received approval from the National Medical Products Administration, China, for its 13-valent vaccine.
Growing R&D for developing novel vaccines boosting the growth of the market. In March 2024, SK Bioscience's announced expansion of its L House vaccine manufacturing facility in South Korea indicates a proactive approach to enhancing vaccine production capacity. This expansion, driven by the joint development of the pneumococcal conjugate vaccine candidate GBP410 with Sanofi, follows positive Phase 2 clinical trial results. SK Bioscience plans to conduct a global Phase 3 clinical trial in 2027, demonstrating a commitment to collaboration and global vaccine development.
Pneumococcal Vaccine Market Report Highlights
Based on type, Pneumococcal Conjugate Vaccine (PCV) segment led the market and is anticipated to grow at the fastest growth over the forecast period. PCV helps protect against pneumococcal disease, a leading cause of death among children under 5 years old
Based on product, Prevnar 13 dominated the market and is expected to grow significantly during the forecast period. The vaccines under the Prevnar brand include Prevnar 13 and Prevnar 20. These are pneumococcal conjugate vaccines (PCVs) designed to protect against pneumococcal disease
Based on end-use, the public sector led the market and is anticipated to grow at the fastest CAGR over the forecast period. The dominance of the public sector in the end use of pneumococcal vaccines, including hospitals, clinics, and healthcare facilities, can be attributed to several factors. These factors include the high prevalence of diseases, government initiatives to increase vaccination coverage
North America dominated the market owing to factors such as advanced healthcare infrastructure, rising prevalence of target diseases, and favorable regulatory environment
Companies Featured
Serum Institute of India Pvt. Ltd.
CSL
Sanofi
GSK plc
Merck & Co., Inc.
Pfizer Inc.
Walvax Biotechnology Co., Ltd
Beijing Minhai Biotechnology Co.,Ltd (Subsidiary of Shenzhen Kangtai Biological Products Co. Ltd.)
Key Attributes:
Report Attribute
Details
No. Of Pages
125
Forecast Period
2023 - 2030
Estimated Market Value (USD) in 2023
$8.07 Billion
Forecasted Market Value (USD) by 2030
$12.19 Billion
Compound Annual Growth Rate
6.2%
Regions Covered
Global
Key Topics Covered:
Chapter 1. Methodology and Scope1.1. Market Segmentation & Scope1.2. Segment Definitions1.3. Research Methodology1.4. Information Procurement1.5. Information or Data Analysis1.6. Market Formulation & Validation1.7. Model Details
Chapter 2. Executive Summary2.1. Market Outlook2.2. Segment Outlook2.2.1. Vaccine Type and Product Outlook2.2.2. End Use Outlook2.2.3. Regional Outlook2.3. Competitive Insights
Chapter 3. Pneumococcal Vaccine Market Variables, Trends & Scope3.1. Market Lineage Outlook3.1.1. Parent Market Outlook3.1.2. Related/ancillary Market Outlook3.2. Market Dynamics3.2.1. Market Driver Analysis3.2.1.1. Increasing Prevalence of Target Disease3.2.1.2. Rising Awareness and Favorable Government Initiatives3.2.1.3. Growing R&D for Developing Novel Vaccines3.2.2. Market Restraint Analysis3.2.2.1. Supply Chain and Vaccine Shortage Challenges3.2.2.2. Vaccine Hesitancy and Public Awareness3.3. Pneumococcal Vaccine Market Analysis Tools3.3.1. Industry Analysis - Porter's3.3.2. PESTEL Analysis
Chapter 4. Pneumococcal Vaccine Market: Vaccine Type Estimates & Trend Analysis4.1. Global Pneumococcal Vaccine Market: Vaccine Type Dashboard4.2. Global Pneumococcal Vaccine Market: Vaccine Type Movement Analysis4.3. Global Pneumococcal Vaccine Market by Vaccine Type, Revenue4.4. Pneumococcal Conjugate Vaccine4.4.1. Pneumococcal Conjugate Vaccine Market Estimates and Forecasts 2018 to 2030 (USD Million)4.5. Pneumococcal Polysaccharide Vaccine4.5.1. Pneumococcal Polysaccharide Vaccine Market Estimates and Forecasts 2018 to 2030 (USD Million)
Chapter 5. Pneumococcal Vaccine Market: Product Estimates & Trend Analysis5.1. Global Pneumococcal Vaccine Market: Product Dashboard5.2. Global Pneumococcal Vaccine Market: Product Movement Analysis5.3. Global Pneumococcal Vaccine Market by Product, Revenue5.4. Prevnar 135.4.1. Prevnar 13 Market Estimates and Forecasts 2018 to 2030 (USD Million)5.5. Synflorix5.6. Pneumovax 235.7. VAXNEUVANCE5.8. PNEUMOSIL5.9. Other Products
Chapter 6. Pneumococcal Vaccine Market: End Use Estimates & Trend Analysis6.1. Global Pneumococcal Vaccine Market: End Use Dashboard6.2. Global Pneumococcal Vaccine Market: End Use Movement Analysis6.3. Global Pneumococcal Vaccine Market by End Use, Revenue6.4. Public Sector6.5. Private Sector
Chapter 7. Pneumococcal Vaccine Market: Regional Estimates & Trend Analysis by Vaccine Type, Product, and End Use7.1. Regional Dashboard7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030
Chapter 8. Competitive Landscape8.1. Recent Developments & Impact Analysis, by Key Market Participants8.2. Company/Competition Categorization8.3. Vendor Landscape8.3.1. List of Key Distributors and Channel Partners8.3.2. Key Customers8.3.3. Key Company Market Share Analysis, 2023
For more information about this report visit https://www.Researchandmarkets.Com/r/mke3vw
About ResearchAndMarkets.ComResearchAndMarkets.Com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
CONTACT: CONTACT: ResearchAndMarkets.Com Laura Wood,Senior Press Manager press@researchandmarkets.Com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900View comments
Comments
Post a Comment